| Product NDC: | 10019-038 | 
| Proprietary Name: | Fentanyl Citrate | 
| Non Proprietary Name: | Fentanyl Citrate | 
| Active Ingredient(s): | 50 ug/mL & nbsp; Fentanyl Citrate | 
| Administration Route(s): | INTRAMUSCULAR; INTRAVENOUS | 
| Dosage Form(s): | INJECTION, SOLUTION | 
| Coding System: | National Drug Codes(NDC) | 
| Product NDC: | 10019-038 | 
| Labeler Name: | Baxter Healthcare Corporation | 
| Product Type: | HUMAN PRESCRIPTION DRUG | 
| FDA Application Number: | ANDA019101 | 
| Marketing Category: | ANDA | 
| Start Marketing Date: | 20100625 | 
| Package NDC: | 10019-038-67 | 
| Package Description: | 10 AMPULE in 1 PACKAGE (10019-038-67) > 2 mL in 1 AMPULE (10019-038-39) | 
| NDC Code | 10019-038-67 | 
| Proprietary Name | Fentanyl Citrate | 
| Package Description | 10 AMPULE in 1 PACKAGE (10019-038-67) > 2 mL in 1 AMPULE (10019-038-39) | 
| Product NDC | 10019-038 | 
| Product Type Name | HUMAN PRESCRIPTION DRUG | 
| Non Proprietary Name | Fentanyl Citrate | 
| Dosage Form Name | INJECTION, SOLUTION | 
| Route Name | INTRAMUSCULAR; INTRAVENOUS | 
| Start Marketing Date | 20100625 | 
| Marketing Category Name | ANDA | 
| Labeler Name | Baxter Healthcare Corporation | 
| Substance Name | FENTANYL CITRATE | 
| Strength Number | 50 | 
| Strength Unit | ug/mL | 
| Pharmaceutical Classes | Full Opioid Agonists [MoA],Opioid Agonist [EPC] |